Susan L Murray1,2, Fergus E Daly1, Patrick O'Kelly1, Eamonn O'Leary3, Sandra Deady3, James P O'Neill4, Alexander Dudley5, Nicholas R Rutledge5, Aiden McCormick5, Diarmuid D Houlihan5, Yvonne Williams1, Patrick G Morris6, Siona Ni Raghallaigh7, Fergal J Moloney8, Donal J Sexton1, Peter J Conlon1,2. 1. Department of Nephrology & Transplantation, Beaumont Hospital, Dublin, Ireland. 2. Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. 3. National Cancer Registry Ireland, Cork Airport Business Park, Cork, Ireland. 4. Department of Otolaryngology, Head & Neck Surgery, Beaumont Hospital, and Royal College of Surgeons, Ireland, Ireland. 5. Hepatology & Liver Transplant Department, St Vincent's University Hospital, Dublin, Ireland. 6. Department of Oncology, Beaumont Hospital, Dublin, Ireland. 7. Department of Dermatology, Beaumont Hospital, Dublin, Ireland. 8. Department of Dermatology, Mater Misericordia University Hospital University College, Dublin, Ireland.
Abstract
Background: Solid organ transplantation is associated with increased risk of non-melanoma skin cancer. Studies with short follow up times have suggested a reduced occurrence of these cancers in recipients treated with mammalian target of rapamycin inhibitors as maintenance immunosuppression. We aimed to describe the occurrence of skin cancers in renal and liver transplant recipients switched from calcineurin inhibitor to sirolimus-based regimes. Methods: We performed a retrospective study of sirolimus conversion within the Irish national kidney and liver transplant programs. These data were linked with the National Cancer Registry Ireland to determine the incidence of NMSC among these recipients. The incidence rate ratio (IRR) for post versus pre-conversion NMSC rates are referred in this study as an effect size with [95% confidence interval]. Results: Of 4,536 kidney transplants and 574 liver transplants functioning on the 1 January 1994 or transplanted between 1 January 1994 and 01 January 1994 and 01 January 2015, 85 kidney and 88 liver transplant recipients were transitioned to sirolimus-based immunosuppression. In renal transplants, the rate of NMSC was 131 per 1000 patient years pre-switch to sirolimus, and 68 per 1000 patient years post switch, with adjusted effect size of 0.48 [0.31 - 0.74] (p = .001) following the switch. For liver transplant recipients, the rate of NMSC was 64 per 1,000 patient years pre-switch and 30 per 1,000 patient years post switch, with an adjusted effect size of 0.49 [0.22 - 1.09] (p .081). Kidney transplant recipients were followed up for a median 3.4 years. Liver transplants were followed for a median 6.6 years.Conclusions: In this study, the conversion of maintenance immunosuppression from calcineurin inhibitors to mTOR inhibitors for clinical indications did appear to reduce the incidence of NMSC in kidney and liver transplant recipients.
Background: Solid organ transplantation is associated with increased risk of non-melanoma skin cancer. Studies with short follow up times have suggested a reduced occurrence of these cancers in recipients treated with mammalian target of rapamycin inhibitors as maintenance immunosuppression. We aimed to describe the occurrence of skin cancers in renal and liver transplant recipients switched from calcineurin inhibitor to sirolimus-based regimes. Methods: We performed a retrospective study of sirolimus conversion within the Irish national kidney and liver transplant programs. These data were linked with the National Cancer Registry Ireland to determine the incidence of NMSC among these recipients. The incidence rate ratio (IRR) for post versus pre-conversion NMSC rates are referred in this study as an effect size with [95% confidence interval]. Results: Of 4,536 kidney transplants and 574 liver transplants functioning on the 1 January 1994 or transplanted between 1 January 1994 and 01 January 1994 and 01 January 2015, 85 kidney and 88 liver transplant recipients were transitioned to sirolimus-based immunosuppression. In renal transplants, the rate of NMSC was 131 per 1000 patient years pre-switch to sirolimus, and 68 per 1000 patient years post switch, with adjusted effect size of 0.48 [0.31 - 0.74] (p = .001) following the switch. For liver transplant recipients, the rate of NMSC was 64 per 1,000 patient years pre-switch and 30 per 1,000 patient years post switch, with an adjusted effect size of 0.49 [0.22 - 1.09] (p .081). Kidney transplant recipients were followed up for a median 3.4 years. Liver transplants were followed for a median 6.6 years.Conclusions: In this study, the conversion of maintenance immunosuppression from calcineurin inhibitors to mTOR inhibitors for clinical indications did appear to reduce the incidence of NMSC in kidney and liver transplant recipients.
Authors: Giorgia L Garrett; Paul D Blanc; John Boscardin; Amanda Abramson Lloyd; Rehana L Ahmed; Tiffany Anthony; Kristin Bibee; Andrew Breithaupt; Jennifer Cannon; Amy Chen; Joyce Y Cheng; Zelma Chiesa-Fuxench; Oscar R Colegio; Clara Curiel-Lewandrowski; Christina A Del Guzzo; Max Disse; Margaret Dowd; Robert Eilers; Arisa Elena Ortiz; Caroline Morris; Spring K Golden; Michael S Graves; John R Griffin; R Samuel Hopkins; Conway C Huang; Gordon Hyeonjin Bae; Anokhi Jambusaria; Thomas A Jennings; Shang I Brian Jiang; Pritesh S Karia; Shilpi Khetarpal; Changhyun Kim; Goran Klintmalm; Kathryn Konicke; Shlomo A Koyfman; Charlene Lam; Peter Lee; Justin J Leitenberger; Tiffany Loh; Stefan Lowenstein; Reshmi Madankumar; Jacqueline F Moreau; Rajiv I Nijhawan; Shari Ochoa; Edit B Olasz; Elaine Otchere; Clark Otley; Jeremy Oulton; Parth H Patel; Vishal Anil Patel; Arpan V Prabhu; Melissa Pugliano-Mauro; Chrysalyne D Schmults; Sarah Schram; Allen F Shih; Thuzar Shin; Seaver Soon; Teresa Soriano; Divya Srivastava; Jennifer A Stein; Kara Sternhell-Blackwell; Stan Taylor; Allison Vidimos; Peggy Wu; Nicholas Zajdel; Daniel Zelac; Sarah T Arron Journal: JAMA Dermatol Date: 2017-03-01 Impact factor: 10.282
Authors: Josefina Alberú; Michael D Pascoe; Josep M Campistol; Francesco P Schena; Maria Del Carmen Rial; Martin Polinsky; John F Neylan; Joan Korth-Bradley; Robert Goldberg-Alberts; Eric S Maller Journal: Transplantation Date: 2011-08-15 Impact factor: 4.939
Authors: Hermina C Wisgerhof; Jeroen R J Edelbroek; Johan W de Fijter; Geert W Haasnoot; Frans H J Claas; Rein Willemze; Jan N Bouwes Bavinck Journal: Transplantation Date: 2010-05-27 Impact factor: 4.939
Authors: Pritesh S Karia; Jamil R Azzi; Eliot C Heher; Victoria M Hills; Chrysalyne D Schmults Journal: JAMA Dermatol Date: 2016-05-01 Impact factor: 10.282
Authors: Donal J Sexton; Patrick O'Kelly; Eamonn O'Leary; Susan Murray; Sandra Deady; Fergus Daly; Jim Egan; Diarmaid D Houlihan; P Aiden McCormick; Patrick G Morris; Siona Ni Raghallaigh; Fergal J Moloney; James Paul O'Neill; Peter J Conlon Journal: JAMA Dermatol Date: 2019-05-01 Impact factor: 10.282
Authors: Greg A Knoll; Madzouka B Kokolo; Ranjeeta Mallick; Andrew Beck; Chieny D Buenaventura; Robin Ducharme; Rashad Barsoum; Corrado Bernasconi; Tom D Blydt-Hansen; Henrik Ekberg; Claudia R Felipe; John Firth; Lorenzo Gallon; Marielle Gelens; Denis Glotz; Jan Gossmann; Markus Guba; Ahmed Ali Morsy; Rebekka Salgo; Earnst H Scheuermann; Helio Tedesco-Silva; Stefan Vitko; Christopher Watson; Dean A Fergusson Journal: BMJ Date: 2014-11-24